Ascendia

  MARKET NEWS

Combangio Awarded $15 Million to Support Ongoing KPI-012 Program for the Treatment of PCED
Aptamers Market is Expected to Reach $342 million
BullFrog AI Partners With the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
Plasticell & LambdaGen Form Collaboration to Develop iPSC-Derived CAR-NK Allogeneic Cancer Immunotherapies
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Artelo Biosciences Initiates Phase 2a Portion of its CAReS Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia & Weight Loss

  FEATURED EDITORIAL

  COMPANY PROFILE

CELEBRATING OVER 100 YEARS. Kahle is the only large-scale automation company in the world that focuses exclusively on custom automated assembly equipment for medical and pharmaceutical devices. For over a century, Kahle has shaped the industry through the use of innovative technologies. Today, we create systems that handle, assemble, inspect, test, and package every medical device imaginable – from syringes, tubing sets and catheters and needle products to diagnostic, pre-filled and combination pharmaceutical devices. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery

Tavros Therapeutics & OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery

Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform, partnership streamlines drug development for novel cancer therapies….

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect

Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses….

Radiant Biotherapeutics Emerges From Stealth Mode With -Million Seed Round & Two Pharma Partnerships

Radiant Biotherapeutics Emerges From Stealth Mode With $8-Million Seed Round & Two Pharma Partnerships

Radiant Biotherapeutics emerged from stealth mode unveiling an $8-million seed financing and two significant pharmaceutical partnerships. The company, based on foundational IP from….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.

Click here to …

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*

Summary

The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

WHITEPAPER - Case Study-Improving Bioavailability Using PBPK Modeling & Parallel Formulation Screening

Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 10 – Capsules
May 17 – Injection Devices